Decision
Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)
Doxecitine and Doxribtimine in the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
Documents
PDF, 456 KB, 8 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 1010 KB, 31 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 1.14 MB, 22 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 155 KB, 4 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 438 KB, 4 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
The scientific opinion was issued on the 02 July 2026 to UCB Pharma Limited in the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years with Doxecitine and Doxribtimine.
For the full EAMS indication please see section 4.1 of the Treatment protocol: Information for healthcare professionals.
The scientific opinion includes:
- a public assessment report (PAR)
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
- Information for NHS Medical Directors
Updates to this page
Published 7 July 2026